Haemostatic Imbalance in Patients With Chronic Liver Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-01

Study Completion Date

2020-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the level of protein C, S ,antithrombin in patients with liver cirrhosis To correlate the level of these parameters with the degree of liver cirrhosis To correlate the level of procoagulants with the level of anticoagulant proteins in liver cirrhosis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renal Function Determination in Patients With Liver Cirrhosis

NCT02047240

Liver Cirrhosis

COMPLETED

Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

NCT06694090

Liver Cirrhosis Portal Hypertension

NOT_YET_RECRUITING

Assessment of Renal Function in Cirrhotic Patients

NCT01895114

Liver Failure Renal Failure

COMPLETED

Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis

NCT02069457

Liver Cirrhosis Portal Vein Thrombosis

COMPLETED

Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in Sohag University Hospital

NCT06953921

Hepatic Encephalopathy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The liver has a cardinal role in the haemostatic system. Liver has the major role in synthesizing all clotting factors and coagulation inhibitors. Under the physiological conditions the balanced levels of procoagulant and anticoagulants determine the risk of hemorrhage and thrombosis.

In chronic liver disease due to chronic hepatitis and underlying cirrhosis, this haemostatic imbalance leads to hypercoagulability which favors thrombosis despite the longer coagulation times of their plasma, compared with that of healthy individuals. The end stage cirrhosis is however predominately associated with bleeding tendency.

Protein C (PC) and protein S (PS) are vitamin K-dependent glycoproteins, that act as natural anticoagulants.

Antithrombin III (AT III) is a natural anticoagulant that is synthesized exclusively in parenchymal cells of the liver The cause of hypercoagulability in chronic liver disease is the reduced level of protein C and increased level of factor VIIIa .As a consequence of hypercoagulability, the deep vein thrombosis, pulmonary embolism, hepatic and portal vein thrombosis may occur.

Varnika et al 2017 found a significantly low protein C value in both chronic hepatitis and cirrhosis group when compared with control group.

Acquired deficiency of АТ III can be caused by decreased synthesis due to damage to hepatic cells Patients with CLD were (and are still) subjected to laboratory screening with the prothrombin and activated partial thromboplastin times (PT and APTT), and those with abnormal values were (are) treated with plasma or procoagulant agents to correct the abnormalities and to prevent haemorrhage during invasive procedures or to stop bleeding from the gastrointestinal tract. Saja et al., and Saray et al 2009 found significantly low protein C value in both chronic hepatitis and cirrhosis group when compared with control group. This was a sign of reduced hepatocyte synthetic capacity in chronic hepatitis. Zocco et al 2009 showed that in CLD reduction in plasma levels of PC correlate with a higher Model For End-Stage Liver Disease (MELD) score. These findings, including the present one, confirm that levels of PC are sensitive markers .

Determination of the levels of AT III and aminotransferase activity in patients with liver disease may be used for differential diagnoses and the monitoring of disease progression.

Little attention had been paid to the fact that, similar to procoagulant factors, their anticoagulant counterparts (namely protein C \[PC\] and antithrombin) are also reduced to the same extent in this setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haemostasis Imbalance in Chronic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 child A

child A liver cirrhosis

Laboratory investigations ( protein C, protein S , antithrombin III)

Intervention Type OTHER

laboratory investigations ( protein C , protein S , antithrombin)

2 child B

child B liver cirrhosis

Laboratory investigations ( protein C, protein S , antithrombin III)

Intervention Type OTHER

laboratory investigations ( protein C , protein S , antithrombin)

3 child C

child C liver cirrhosis

Laboratory investigations ( protein C, protein S , antithrombin III)

Intervention Type OTHER

laboratory investigations ( protein C , protein S , antithrombin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory investigations ( protein C, protein S , antithrombin III)

laboratory investigations ( protein C , protein S , antithrombin)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed as liver cirrhosis confirmed clinical , biochemical and ultrasonography.
* severity of cirrhosis was assessed according to Child-Pugh score and MELD score.

Exclusion Criteria

* history of bleeding or thrombotic disorder,
* history of renal disease, diabetes mellitus,
* ongoing or recent pregnancy,
* recent history of transfusion of blood products,
* current anticoagulation therapy.
* Hepatocellular carcinoma

Eligible Sex

ALL

Accepts Healthy Volunteers

No